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ABSTRACT
Introduction: The objective of this study was to 
compare the relative bioavailability of the US Food 
and Drug Administration-approved formulation 
of colchicine after a single 0.6 mg dose in young 
(18–30 years of age) and elderly (≥60 years of age) 
healthy subjects to determine whether dosing 
adjustments are required in elderly patients.
Methods: A single-dose, single-drug, parallel-
group study was performed in 20 young subjects 
with normal renal function (defined as creatinine 
clearance [CrCl] ≥80 mL/min) and 18 elderly 
subjects with normal or mild renal impairment 
(CrCl ≥50 mL/min) in otherwise good health. 
Blood samples were collected for up to 72 hours 
postdose and analyzed for colchicine using a 
validated liquid chromatography/tandem mass 
spectrometry method. Noncompartmental 
pharmacokinetic parameters were compared 
using analysis of variance methods.
Results: There were no statistically significant 
(P < 0.05) differences in mean colchicine 
pharmacokinetic parameters between young 
and elderly subjects, including peak plasma 
concentration (Cmax) (2.53 vs. 2.56 ng/mL), 
time to Cmax (1.25 vs. 1.25 hours), area under 
the plasma concentration-time curve to infinity 
(22.29 vs. 25.01 ng/h/mL), elimination half-life 
(25.4 vs. 30.1 hours), oral clearance (0.40 vs. 
0.35 L/h/kg), and apparent volume of 
distribution (14.3 vs. 14.8 L/kg), respectively.
Conclusion: The lack of any significant 
differences in colchicine pharmacokinetic 
parameters between young and elderly healthy 
subjects, with some of the latter including 
mild renal impairment, suggests that dose 
modification of colchicine may not be necessary 
in healthy elderly patients. However, when 
evaluating the use of colchicine dosing in an 
elderly patient, the confounding effect on 
overall exposure and safety from comorbid 
conditions, the use of concomitant medications, 
and the administration of multiple doses should 
be considered.
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triphosphate-dependent phosphoglycoprotein 
that is located in the cell membranes of 
numerous tissues, is responsible for the efflux 
of colchicine across membranes, including 
within enterocytes of the intestine. P-gp plays a 
predominant role in the incomplete absorption 
of colchicine (mean absolute bioavailability 
is approximately 45%), the enterohepatic 
recirculation that occurs as evidenced by 
secondary peak plasma concentrations and for 
many potential drug–drug interactions (e.g., 
cyclosporin) [5, 6].
Colchicine also undergoes hepatic 
biotransformation by cytochrome 3A4 
(CYP3A4) to form three minor metabolites 
(2-O-demethylcolchicine, 3-O-demethylcolchicine, 
and 10-O-demethylcolchicine) that account for 
less than 5% of the parent compound in human 
plasma [4]. CYP3A4 inhibition of colchicine by 
certain drugs (e.g., macrolides, statins) has the 
potential to induce colchicine toxicity by dual 
modulation of both P-gp and CYP3A4 [6].
There is little information on the 
potential effect of age, gender, or race on the 
pharmacokinetics of colchicine. A published 
study investigated the pharmacokinetics of 
colchicine in six healthy young men and four 
elderly women after single-dose administration 
intravenously (i.v.) (0.5 mg in young men and 
1 mg in elderly women) and orally (1 mg in each 
group) [8]. Mean absolute bioavailability was 
similar in the young men and elderly women 
(44% vs. 45%, respectively), whereas peak plasma 
concentration (Cmax) was approximately twofold 
higher in the elderly women compared with 
the young men (5.5 vs. 12 ng/mL). Following 
i.v. administration, the volume of distribution 
at steady state (4.2 vs. 2.9 L/kg) and total body 
clearance (10.5 vs. 5.5 L/h) were reduced in the 
elderly women.
The pharmacokinetics of the currently 
approved formulation of colchicine have been 
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INTRODUCTION
The prevalence of gout is increasing due to 
various factors, including the aging population 
and dietary/lifestyle changes [1, 2]. The National 
Health and Nutrition Examination Survey 
(NHANES) estimated the prevalence of gout in 
the US population between 2007 and 2008 to 
be 8.3 million adults (≥20 years of age), affecting 
6.1 million men (5.9% of the population) and 
2.2 million women (2.0% of the population) [3]. 
The overall prevalence of gout has increased from 
2.7% (NHANES III, 1988–1994) to 3.9% (NHANES, 
2007–2008) [3].
Colchicine 0.6 mg is indicated for the 
prophylaxis and treatment of acute gout 
attacks in adults and the treatment of familial 
Mediterranean fever in adults and children 
4 years of age and older [4]. There is limited 
information on the effect of age on the 
pharmacokinetics of colchicine.
Colchicine binds to β-tubulin heterodimers 
that comprise microtubules, disrupting the 
cytoskeleton and inducing various signaling 
pathways and cellular events, eventually 
resulting in its anti-inflammatory mechanism 
of action in the treatment of gout [5, 6]. 
Although the exact mechanism has not been 
completely elucidated, colchicine inhibits the 
inflammasome complex in neutrophils and 
monocytes, interfering with the activation of the 
proinflammatory cytokine interleukin-1β [7]. The 
ubiquitous nature of microtubules contributes 
to the apparent volume of distribution (Vd/F) 
of colchicine, which greatly exceeds total body 
volume, and the slow dissociation half-life (T1/2) 
of the tubulin–colchicine complex (20–30 hours) 
contributes to the prolonged plasma elimination 
half-life [5]. P-glycoprotein (P-gp), the adenosine 
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history of psychiatric disorders within the 
previous 2 years that required hospitalization 
or medication; use of pharmacologic agents 
known to induce or inhibit drug-metabolizing 
enzymes (especially CYP3A4) within 30 days 
before dosing; use of a study drug in a research 
investigation within 30 days before dosing; 
history of treatment for drug or alcohol 
addiction, or excessive alcohol consumption 
(>14 units/week on average) within the previous 
year; positive test result for drug abuse; use of 
tobacco products within 90 days before dosing; 
positive HIV, hepatitis B surface antigen, or 
hepatitis C antibody test; difficulty in fasting or 
eating standard meals; donation or significant 
loss of whole blood (≥480 mL) within 30 days 
or plasma within 14 days before dosing; 
inability or unwillingness to tolerate multiple 
venipuncture; and women with a positive 
serum pregnancy test result, who were likely to 
become pregnant during the study, or who were 
lactating. Furthermore, women of childbearing 
potential had to be prepared to abstain from 
sexual intercourse or have used and continue to 
use a reliable method of contraception (e.g., use 
of condom with spermicide, intrauterine device, 
hormonal contraception) 30 days before dosing 
and throughout the study.
Study Design
The study protocol received ethics committee 
approval (Novum Independent Institutional 
Review Board). All subjects provided written 
informed consent before study participation, which 
was conducted in accordance with the US Code of 
Federal Regulations and International Conference 
on Harmonisation Guidelines for Good Clinical 
Practice, and adhered to the ethical principles of the 
Declaration of Helsinki. The study was performed 
at a single study center (Novum Pharmaceutical 
Research Services, Las Vegas, Nevada, USA).
reported in the US prescribing information [4], 
reviews [5, 9], and studies in young subjects [10, 11], 
but the potential effect of age per se on drug 
disposition of this formulation has not been 
formally investigated until now. The objective of 
this study was to compare the pharmacokinetics 
of colchicine following the oral administration of 
a single 0.6 mg tablet of the approved colchicine 
formulation when given to young (18–30 years 
of age) and elderly (≥60 years of age) healthy 
subjects following an overnight fast.
METHODS
Subjects
Adult male and female subjects with a body mass 
index of 18–30 kg/m2 who were either young 
(18–30 years of age) or elderly (>60 years of age) 
were eligible for recruitment if they were in good 
health on the basis of medical history, physical 
examination, and routine laboratory tests. Elderly 
subjects with normal renal function (defined as 
creatinine clearance [CrCl] ≥80 mL/min) or with 
mild renal impairment (defined as CrCl between 
50 and 80 mL/min) were allowed to participate, 
whereas young subjects were required to have 
normal renal function. The Cockcroft–Gault 
formula was used to measure CrCl.
Exclusion criteria included history of allergy 
or sensitivity to colchicine; history of any 
drug hypersensitivity or intolerance likely to 
compromise the safety of the subject or the 
study in the investigator’s opinion; significant 
history or current evidence of chronic infectious 
disease, system disorders, organ dysfunction 
(especially cardiovascular disorders), stroke, 
renal or hepatic disorder, diabetes, or bleeding 
disorders; presence of gastrointestinal disease or 
history of malabsorption in the previous year; 
presence of any medical condition requiring 
regular treatment or prescription drug treatment; 
554 Adv Ther (2012)  29(6):551–561.
Following a screening period of up to 
4 weeks, all subjects received a single 0.6 mg 
colchicine tablet administered with 240 mL of 
water at room temperature. They were instructed 
to swallow the tablet whole without chewing or 
biting. Dosing order was randomly assigned by 
age group in blocks of two.
All subjects checked into the clinical 
investigation facility on day 1 with an evening 
meal served and consumed more than 10 hours 
before dosing. No food or beverages (except 
water) were permitted until 4 hours after study-
drug administration on day 1. Standardized meals 
and snacks were served at approximately 4, 9, 
and 13 hours after dosing during confinement 
in the test facility. Blood sample collections were 
performed before meals if sampling and meal 
times coincided. No caffeine, xanthine, alcohol, 
or grapefruit products were permitted during 
confinement; subjects were also instructed to 
abstain from any food or beverages containing 
these products within 48 hours before dosing and 
throughout the period of blood sample collection. 
During the confinement period of the study, 
additional fluids were not permitted from 1 hour 
before to 1 hour after dosing except for the water 
administered with the test dose. Otherwise, water 
was freely encouraged, although no fluids other 
than water or those served with standardized 
meals were permitted. Subjects left the clinical 
facility approximately 24 hours after test dose 
administration (day 2) but returned to provide 36, 
48, 60, and 72-hour blood sample collections.
Subjects were not permitted to take 
prescription medications except for hormonal 
contraception within 2 weeks before dosing 
and over-the-counter medications including 
vitamins and herbal products within 3 days 
before dosing and throughout the duration of 
blood sample collection.
Subjects were advised that they could withdraw 
from the study at any time for any reason. 
Furthermore, the investigator could withdraw 
subjects from the study to protect their health or 
for noncompliance with study procedures. Any 
subject experiencing vomiting within 3 hours 
after dosing (based on twice the expected time 
to Cmax [Tmax] of ~1.5 hours) would be dropped 
from analysis. No subjects were discontinued 
because of these criteria.
Medical history, physical examination, 
12-lead electrocardiography, routine laboratory 
tests, drug screen, virology tests for HIV and 
hepatitis viruses, and serum pregnancy test were 
performed during the 4-week screening period. 
Vital signs were measured during the screening 
period and on days –1, 1, and 2, with regular 
testing on day 1 before dosing and at regular 
intervals after dosing. Urine pregnancy test and 
repeat drug screen were performed on admission 
to the clinical facility on day –1. Medical history 
was reviewed again on day 2, on days 3–4, and 
on discharge from the clinical facility. Routine 
laboratory tests were also repeated at discharge 
from the clinical facility. Any undesirable sign, 
symptom, or medical condition occurring 
after starting the study, whether reported 
spontaneously, in response to questioning, or 
directly observed, was recorded regardless of 
suspected relation to the study medication. 
All treatment-emergent adverse events (AEs) 
were recorded (coded using MedDRA version 
12.0 adverse event dictionary) and were graded 
by intensity (mild, moderate, or severe) and 
relationship to the study drug (unlikely, possible, 
or probable) by the investigator.
Pharmacokinetic Measurements
Venous blood samples (6 mL in prechilled EDTA 
tubes) were taken by direct venipuncture at 
0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 16, 18, 24, 36, 48, 60, and 72 hours 
postdose. Samples were mixed by gently inverting 
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the tubes several times and centrifuged at 
approximately 2,700–3,000 rpm for 10 minutes 
at 4°C. Plasma samples were collected into 
polypropylene tubes and stored frozen to at 
least –18°C until analysis. The time from blood 
collection to being centrifuged was less than 
60 minutes and to plasma being frozen was less 
than 120 minutes. Frozen plasma samples on 
dry ice were transported overnight for assay at a 
single analytical laboratory (Frontage Laboratories, 
Inc, Malvern, Pennsylvania, USA) using a liquid 
chromatography/tandem mass spectrometry (LC/
MS/MS) method. For assay, 100 µL of thawed 
plasma was mixed with 20 µL of diluent 1 
(methanol/water, 50:50), 20 µL of internal standard 
(colchicine-d3 5 ng/mL), and 300 µL of diluent 2 
(ammonium formate 400 nmol/L in water). Then, 
1.5 mL of extraction solvent (methyl tert-butyl 
ether/ethyl acetate, 60:40) was added, mixed for 
10 minutes, and centrifuged for 5 minutes at 
3,000 rpm. The organic layer was removed, dried 
at 35°C under nitrogen using an evaporator for 
approximately 20 minutes, and reconstituted in 
200 µL of mobile phase (methanol/ethyl acetate, 
60:40, with ammonium formate 2 mmol/L). 
A 20-µL aliquot was injected (Shimadzu liquid 
chromatography pump and autosampler) onto 
LC/MS/MS (Sciex API 5000). A Synergi Polar-RP, 
50 × 2.0 mm, 4-µm column was used with a pump 
flow rate of 0.6 mL/min. Analysis was performed 
in positive ionization mode, with colchicine 
and internal standard identified by the multiple 
reaction monitoring transitions m/z 400.2 → 310.1 
and m/z 402.1 → 310.1, respectively. The assay 
calibration range was 0.02–20 ng/mL for analytical 
runs with a lower limit of quantitation of 
0.02 ng/mL. Intraday accuracy was 99.1–110.0% 
with intraday precision of 2.35–17.54 coefficient 
of variation (%CV), and interbatch accuracy was 
99.17–100.05% (1.92–13.32 %CV).
Model-independent pharmacokinetic 
parameters for colchicine were determined 
using the SAS (version 9.1.3 or later), including 
Cmax; Tmax; AUC0–t (area under the plasma 
concentration-time curve [AUC] from time 
zero to time t, where t is the time of the last 
measurable concentration [Ct] calculated using 
the linear trapezoidal method); AUC0–∞ (AUC 
from time zero extrapolated to infinity calculated 
as AUC0–t + Ct/Kel, where Ct is the last measurable 
drug concentration and Kel is the elimination rate 
constant estimated via linear regression of the 
terminal portion of the log concentration versus 
time curve); T1/2 (elimination half-life calculated 
as ln[2]/Kel); CL/F (apparent clearance calculated 
as the dose/AUC0–t); and Vd/F (apparent volume 
of distribution, calculated as CL/Kel).
Statistical Analysis
Descriptive statistics (mean ± SD) were used 
to summarize the pharmacokinetic data for 
each age group. Analyses of variance (ANOVA) 
were performed using the general linear model 
procedure of SAS (version 9.1.3 or later) with 
hypothesis testing for study-drug effects at 
α = 0.05. The statistical model contained the 
main effect of group. Least square means for the 
groups (LSMEANS statement), the differences 
between adjusted group means, and the 
standard errors associated with these differences 
(ESTIMATE statement) were calculated. 
Comparison of Cmax, AUC0–t, and AUC0–∞ 90% 
confidence intervals (CI) for each group was 
constructed to test two one-sided hypotheses 
at the α = 0.05 level of significance, with 
confidence intervals presented for the geometric 
mean ratios obtained from logarithmic (ln)-
transformed data. In addition, the relationship 
between colchicine pharmacokinetic parameters 
and covariates including age and CrCl were 
investigated by linear regression analysis. 
Post-hoc analysis of differences in race and 
gender (n = 38) was also performed.
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RESULTS
Baseline demographic and clinical characteristics 
for the 38 subjects (20 young and 18 elderly; 
20 women and 18 men; 14 African American, 
15 white, and 9 “other”) included in the 
statistical analysis are summarized in Table 1. 
Elderly subjects in this study had a median age 
of 62 years and a mean age of 62.8 ± 2.83 years. 
No subjects older than 70 years were enrolled 
in the study. The age groups were balanced 
for weight and body mass index. There were 
significant differences in mean age (P < 0.001) 
and CrCl (P < 0.001) between the young 
and elderly groups. There was a statistically 
significant difference (P < 0.001) in CrCl between 
age groups (132 ± 23.2 mL/min for young 
vs. 87.0 ± 17.9 mL/min for elderly subjects). 
Table 1  Baseline demographic and clinical characteristics
Characteristic Young subjects Elderly subjects
(n = 20) (n = 18)
Gender, n (%)
Male 8 (40.0) 10 (55.6)
Female 12 (60.0) 8 (44.4)
Ethnicity, n (%)
Hispanic 4 (20.0) 3 (16.7)
Non-Hispanic 16 (80.0) 15 (83.3)
Race, n (%)
American Indian or Alaska Native 0 2 (11.1)
Black or African American 13 (65.0) 1 (5.6)
White 3 (15.0) 12 (66.7)
Other 4 (23.5) 3 (16.7)
Median age, year (range) 25 (18–30) 62 (60–70)
Mean age, year ± SD 24.41 ± 3.66* 62.83 ± 2.83*
Median height, cm (range) 172.2 (154.9–188.0) 167.6 (152.4–180.3)
Mean height, cm ± SD 67.29 ± 3.62 65.50 ± 3.42
Median weight, kg (range) 80.3 (52.6–95.3) 71.2 (61.2–92.5)
Mean weight, kg ± SD 170.53 ± 26.20 162.94 ± 21.69
Median body mass index, kg/m2 (range) 25.8 (20.4–29.9) 27.6 (20.4–30.0)
Mean body mass index, kg/m2 ± SD 26.19 ± 2.81 26.54 ± 3.19
Median CrCl, mL/min (range) 123 (83–183)* 86.0 (57–120)*
Mean CrCl, mL/min ± SD 132.56 ± 23.16* 87.02 ± 17.92*
CrCl creatinine clearance
* P < 0.001 between groups
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ratio for women to men was 1.21, a difference 
deemed not clinically meaningful. The mean 
Cmax for colchicine was similar in the young and 
elderly groups (2.61 vs. 2.56 ng/mL, respectively). 
Race was predominantly black among the 
young subjects and white among the elderly 
subjects, with a significant between-group 
difference (P < 0.001). All 38 subjects were 
evaluated for safety.
Mean plasma concentration-time profiles for 
colchicine in the young and elderly subjects are 
graphically presented in Fig. 1. The arithmetic 
mean pharmacokinetic parameters for colchicine 
in the young and elderly groups are summarized 
in Table 2. Statistical comparisons revealed no 
statistically significant (P < 0.05) differences 
between the age groups for any of the colchicine 
pharmacokinetic parameters.
The relationship between exposure to colchicine 
(AUC) and CrCl is presented graphically in Fig. 2. 
A trend for higher colchicine systemic exposure 
with decreasing renal function (as measured by 
CrCl) was seen; however, the magnitude of the 
differences was small and not clinically meaningful. 
With regard to gender, there was a significant 
difference (P < 0.05) in AUCs; however, the mean 
Table 2  Arithmetic mean pharmacokinetic parameters by age group for colchicine administered as a single 0.6-mg tablet to 
healthy subjects (n = 38)
Parameter Arithmetic mean ± SD (%CV) P value for between-group 
comparison Young Elderly
(n = 20) (n = 18)
AUC0–t (ng/h/mL) 19.95 ± 5.86 (29.4) 21.88 ± 6.22 (28.4) 0.3311
AUC0–∞ (ng/h/mL) 22.39 ± 6.95 (31.3) 25.01 ± 6.92 (27.7) 0.2352
Cmax (ng/mL) 2.61 ± 0.71 (27.6) 2.56 ± 0.97 (38.0) 0.9237
Tmax (h) 1.38 ± 0.42 (39.6) 1.25 ± 0.43 (34.3) 0.9869
Kel (h–1) 0.028 ± 0.006 (20.3) 0.025 ± 0.01 (28.7) 0.1459
T1/2 (h) 24.9 ± 5.34 (20.6) 30.06 ± 10.78 (35.9) 0.0936
CL/F (L/h/kg) 0.400 ± 0.121 (30.1) 0.351 ± 0.10 (29.0) 0.1876
Vd/F (L/kg) 14.3 ± 4.31 (30.0) 14.8 ± 5.59 (37.8) 0.7854
AUC0–t area under the plasma concentration-time curve to the last measurable time point, AUC0–∞ area under the plasma 
concentration-time curve to time infinity, Cmax peak plasma concentration, %CV coefficient of variation, Tmax time to reach 
Cmax, Kel  elimination rate constant, t1/2 terminal half-life, CL/F apparent clearance, Vd/F apparent volume of distribution
Fig. 1  Mean plasma colchicine concentrations following 
oral administration of a single 0.6 mg colchicine tablet to 
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The Cmax ratio (elderly/young) for colchicine 
was close to unity (0.989 [90% CI 0.81–1.16]). 
The AUC0–t and AUC0–∞ ratios for colchicine 
were slightly less than unity (0.91 [90% CI 
0.76–1.06] and 0.89 [90% CI 0.74–1.04], 
respectively), indicating marginally higher 
exposure to colchicine in the elderly patients, 
although the difference was not significant 
(P > 0.05). The mean elimination T1/2 was 
slightly longer in subjects aged 60 years and 
older than in those 18–30 years of age; however, 
this was not significant (P > 0.05). Furthermore, 
there were no differences in oral clearance (CL/F; 
P > 0.05) or apparent volume of distribution (Vd/F; 
P = 0.7854) between age groups.
Table 3  Study-drug emergent adverse events (n = 38)
AE Subjects, n (%)
Young Elderly
(n = 20) (n = 18)
Any AE 7 (35.0) 8 (44.4)
AE by preferred terma
Increased BPb 1 (5.0) 7 (38.9)
Somnolencec 1 (5.0) 2 (11.1)
Headachec 2 (10.0) 0
Tinnitusc 0 1 (5.6)
Abdominal discomfortc 1 (5.0) 0
Abdominal pain (upper)c 1 (5.0) 0
Nauseac 1 (5.0) 0
Feeling hotc 0 1 (5.6)
BP decreasedb 1 (5.0) 0
Heart rate increasedb 1 (5.0) 0
Dizzinessc 0 1 (5.6)
Nasal congestionb 1 (5.0) 0
AE adverse event, BP blood pressure
a According to MedDRA version 12.0
b Relationship to drug unlikely
c Relationship to drug possible
Fig. 2  Colchicine exposure (AUC) versus creatinine clearance. 
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ANOVA comparisons by gender showed 
slightly higher Cmax (2.76 vs. 2.38 ng/mL) and 
AUC (26.2 vs. 21.7 ng/h/mL) in female subjects, 
differences that were not statistically significant 
(P > 0.05). Furthermore, no significant gender 
differences were seen in Tmax, AUC, CL/F, Vd/F, 
or T1/2. There were no significant differences in 
colchicine pharmacokinetic parameters between 
the racial groups.
A total of 15 of the 38 subjects reported 
22 treatment-emergent AEs, with seven in the 
young group and eight in the elderly group (Table 3). 
None of the AEs was considered serious. All 
22 AEs were classified as mild in intensity and 
resolved spontaneously before study completion. 
The AE relationship to drug was considered 
unlikely (n = 11) or possible (n = 11). The most 
frequent AEs were increased blood pressure 
(n = 8) and somnolence (n = 3). The occurrence 
of gastrointestinal disturbances related to therapy 
with multiple doses of colchicine is typically 
higher (26% in a clinical trial of patients with 
acute gout flare) [4] than was reported in this 
single-dose study of colchicine (5%). This same 
clinical study does not, however, account for 
the rate of increased blood pressures observed 
in the present study (5% young subjects [n = 1] 
and 38.9% elderly subjects [n = 7]) [4]. For the 
occurrence of increased blood pressure, it was 
determined that a relationship to study drug in 
this study was unlikely.
DISCUSSION
The study sought to compare the relative 
bioavailability of the US Food and Drug 
Administration (FDA)-approved formulation 
of colchicine after a single 0.6 mg dose in 
young (18–30 years of age) and elderly healthy 
subjects (≥60 years of age) to determine 
whether dosing adjustments are required in 
elderly patients. There were two identifiable, 
potential limitations to this study. First, the age 
of the elderly population was limited to a range 
of 60–70 years to avoid potential confounding 
issues of renal dysfunction. Second, the study 
evaluated only healthy subjects without 
comorbid conditions, such as gout, because 
FDA guidance on drug–drug interaction studies 
indicate that it is reasonable to study healthy 
volunteers. In addition, elderly patients 
with mild renal impairment were allowed to 
participate at the discretion of the investigator 
because they are generally considered to be 
healthy and adjustment of dosing is not required 
for treatment of gout flare, prophylaxis of gout 
flare, and familial Mediterranean fever. However, 
patients should be monitored closely [4].
Single-dose colchicine 0.6 mg was well 
tolerated in young and elderly healthy subjects. 
There were no clinically meaningful differences in 
colchicine pharmacokinetic parameters (i.e., Cmax, 
AUC, T1/2, and CL/F) between young and elderly 
healthy subjects, including those with mild renal 
impairment. In addition, there were no statistically 
significant differences (P < 0.05) observed in the 
comparisons of the pharmacokinetic parameters 
by race or gender. Although the study was not 
designed to examine gender or race differences in 
colchicine pharmacokinetics, comparisons were 
performed on the pooled data across the two age 
groups by gender and race.
CONCLUSION
The only previous recommendation for colchicine 
dosing was reported by Terkeltaub [12], who 
suggested that the recommended maintenance 
dose of colchicine should be reduced by half in 
patients 70 years of age or older. These data were 
empirical and not based on actual study results.
In this study, the lack of any clinically 
meaningful differences in colchicine 
pharmacokinetic parameters between healthy 
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young and elderly subjects, with some of the 
latter having mild renal impairment, suggests 
that dose modification of colchicine according 
to age may not be necessary in adults. These 
findings require confirmation in patients 
with gout and, in general, dose selection 
for colchicine in elderly patients with gout 
should be performed with caution, taking 
into consideration the presence of comorbid 
conditions, concomitant medications, and 
multiple doses.
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